Efficacy of Eravacycline Versus Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) Acinetobacter baumannii
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280221085551
Abstract: Background Multidrug-resistant Acinetobacter baumannii remains challenging to treat. Although eravacycline has in vitro activity against this pathogen, there are no studies evaluating outcomes. Objective To assess the efficacy of eravacycline compared with best previously available… read more here.
Keywords: previously available; best previously; therapy; therapy adults ... See more keywords
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood-2017-05-785790
Abstract: Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis and leukemia. Patients resistant/intolerant to hydroxycarbamide (HC) have a poor outlook. MAJIC (ISRCTN61925716) is a… read more here.
Keywords: ruxolitinib; trial; best available; available therapy ... See more keywords
HOW TO OPTIMALLY SEQUENCE AVAILABLE THERAPY LINES IN ADVANCED PROSTATE CANCER
Sign Up to like & getrecommendations! Published in 2022 at "Acta Clinica Croatica"
DOI: 10.20471/acc.2022.61.s3.5
Abstract: Optimal sequencing of available therapy lines in patients with advanced prostate cancer often poses quite a challenge. The guidelines are sometimes equivocal and clinical trial data are not always applicable to a particular patient. There… read more here.
Keywords: prostate cancer; therapy lines; therapy; available therapy ... See more keywords